CellControl and BioInvent sign Phase III Manufacturing Agreement for ACA 125 Antibody
CellControl and BioInvent sign Phase III Manufacturing Agreement for ACA 125 Antibody Martinsried, Germany, and Lund, Sweden; 5 April 2002: CellControl Biomedical Laboratories AG and BioInvent International AB today announce an agreement for the large scale cGMP (current Good Manufacturing Practise) manufacturing of CellControl's ACA-125 antibody. The ACA-125 is an imitation of the natural antigen CA 125 which is present in 80 percent of ovarian carcinomas. When injected, the substance causes a specific immune reaction to CA 125 in the patient's body. A tumour vaccine on this basis promises